Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial

被引：0
|
作者：
Enrico Tiacci
Luca De Carolis
Edoardo Simonetti
Mara Merluzzi
Antonio Bennati
Vincenzo Maria Perriello
Alessandra Pucciarini
Alessia Santi
Alessandra Venanzi
Valentina Pettirossi
Gianluca Schiavoni
Luisa Tasselli
Stefano Ascani
Stefano Volpetti
Brunangelo Falini
机构：
[1] University and Hospital of Perugia,Hematology
[2] University of Perugia and Hospital of Terni,Anatomic Pathology
[3] Azienda Sanitaria Universitaria Integrata,Clinica Ematologica
来源：
Leukemia | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3314 / 3318
页数：4
相关论文
共 50 条
  • [1] Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
    Tiacci, Enrico
    De Carolis, Luca
    Simonetti, Edoardo
    Merluzzi, Mara
    Bennati, Antonio
    Perriello, Vincenzo Maria
    Pucciarini, Alessandra
    Santi, Alessia
    Venanzi, Alessandra
    Pettirossi, Valentina
    Schiavoni, Gianluca
    Tasselli, Luisa
    Ascani, Stefano
    Volpetti, Stefano
    Falini, Brunangelo
    LEUKEMIA, 2021, 35 (11) : 3314 - 3318
  • [2] Efficacy and Safety of the BRAF Inhibitor Vemurafenib in Hairy Cell Leukemia Patients Refractory to or Relapsed after Purine Analogs: A Phase-2 Italian Clinical Trial
    Tiacci, Enrico
    De Carolis, Luca
    Zinzani, Pier Luigi
    Pulsoni, Alessandro
    Zaja, Francesco
    Cimminiello, Michele
    Ambrosetti, Achille
    Rossi, Davide
    Motta, Giovanna
    Varettoni, Marzia
    Fraticelli, Vincenzo
    Carella, Angelo Michele
    Anastasia, Antonella
    Leoni, Pietro
    Rambaldi, Alessandro
    Pileri, Stefano Aldo
    Foa, Robin
    Falini, Brunangelo
    BLOOD, 2014, 124 (21)
  • [3] Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia
    Park, Jae H.
    Chung, Stephen S.
    Chung, Young Rock
    Won, Helen
    Teruya-Feldstein, Julie
    Berger, Michael
    Khawaja, Talal T.
    Lacouture, Mario E.
    Levine, Ross L.
    Abdel-Wahab, Omar
    Tallman, Martin S.
    BLOOD, 2013, 122 (21)
  • [4] THE BRAF INHIBITOR VEMURAFENIB IS SAFE AND HIGHLY EFFECTIVE IN REFRACTORY AND RELAPSED HAIRY CELL LEUKEMIA: RESULTS OF THE HCL-PG01 PHASE-2 ITALIAN CLINICAL TRIAL
    Tiacci, E.
    De Carolis, L.
    Broccoli, A.
    Pulsoni, A.
    Mazzucco, M.
    Cimminiello, M.
    Ambrosetti, A.
    Rossi, D.
    Motta, G.
    Varettoni, M.
    Fraticelli, V.
    Carella, A. M.
    Anastasia, A.
    Leoni, P.
    Rambaldi, A.
    Falzetti, F.
    Ascani, S.
    Capponi, M.
    Martelli, M. P.
    Pileri, S. A.
    Foa, R.
    Zinzani, P. L.
    Falini, B.
    HAEMATOLOGICA, 2015, 100 : 1 - 2
  • [5] Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib
    V. Vergote
    D. Dierickx
    A. Janssens
    G. Verhoef
    T. Tousseyn
    P. Vandenberghe
    P. Wolter
    M. Delforge
    Annals of Hematology, 2014, 93 : 2087 - 2089
  • [6] Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib
    Vergote, V.
    Dierickx, D.
    Janssens, A.
    Verhoef, G.
    Tousseyn, T.
    Vandenberghe, P.
    Wolter, P.
    Delforge, M.
    ANNALS OF HEMATOLOGY, 2014, 93 (12) : 2087 - 2089
  • [7] Cotreatment of Hairy Cell Leukemia and Melanoma With the BRAF Inhibitor Dabrafenib
    Blachly, James S.
    Lozanski, Gerard
    Lucas, David M.
    Grever, Michael R.
    Kendra, Kari
    Andritsos, Leslie A.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (01): : 9 - 13
  • [8] Efficacy and Safety of Obinutuzumab in Relapsed or Refractory Hairy Cell Leukemia (R/R HCL): An Italian Multicenter Phase-2 Academic Trial (HCL-PG04)
    Tiacci, Enrico
    De Carolis, Luca
    Capponi, Monia
    Falcinelli, Flavio
    Zaja, Francesco
    Pulsoni, Alessandro
    Simonetti, Edoardo
    Montechiarello, Elisa
    Romano, Alessandra
    Olivieri, Jacopo
    Mancini, Alessandro
    D'Elia, Gianna Maria
    Foa, Robin
    Frezzato, Maurizio
    Falini, Brunangelo
    BLOOD, 2023, 142
  • [9] VEMURAFENIB IS SAFE AND HIGHLY ACTIVE IN HAIRY CELL LEUKEMIA PATIENTS REFRACTORY TO OR RELAPSED AFTER PURINE ANALOGS: A PHASE-2 ITALIAN CLINICAL TRIAL
    Tiacci, E.
    De Carolis, L.
    Zinzani, P. L.
    Pulsoni, A.
    Mazzucco, M.
    Cimminiello, M.
    Ambrosetti, A.
    Rossi, D.
    Motta, G.
    Varettoni, M.
    Fraticelli, V.
    Carella, A. M.
    Anastasia, A.
    Leoni, P.
    Rambaldi, A.
    Pileri, S. A.
    Foa, R.
    Falini, B.
    HAEMATOLOGICA, 2014, 99 : 245 - 246
  • [10] Co-Treatment Of Hairy Cell Leukemia and Melanoma With The BRAF Inhibitor Dabrafenib
    Andritsos, Leslie A.
    Blachly, James S.
    Kendra, Kari
    Lozanski, Gerard
    Greyer, Michael R.
    BLOOD, 2013, 122 (21)
12345